DEXRAZOXANE FOR INJECTION DIN 02544083
Health Canada record
| Active ingredient(s) | DEXRAZOXANE 250 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | V03AF02 DEXRAZOXANE |
| Original market date | 21-Jun-2025 |
| Current status date | 06-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Juno Pharma Canada Inc. — licence 3-002916, currently licensed, last inspection rating C (2025-11-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEXRAZOXANE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02557649 | DEXRAZOXANE FOR INJECTION | HIKMA CANADA LIMITED | Powder For Solution | DEXRAZOXANE 250 MG | Marketed |
| 02153432 | ZINECARD | PFIZER CANADA ULC | Powder For Solution | DEXRAZOXANE 250 MG | Marketed |
| 02544091 | DEXRAZOXANE FOR INJECTION | JUNO PHARMA CANADA INC. | Powder For Solution | DEXRAZOXANE 500 MG | Cancelled Pre Market |
| 02153440 | ZINECARD | PFIZER CANADA ULC | Powder For Solution | DEXRAZOXANE 500 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37850 | 2026-07-06 | Abbreviated New Drug Submission (ANDS) | Administrative: Merger/Buy-out |
| 32410 | 2023-12-28 | Abbreviated New Drug Submission (ANDS) |
International API supply for DEXRAZOXANE
9 active FDA Drug Master Files.
Request a quote for DEXRAZOXANE FOR INJECTION